TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Ketamine and Methadone on Postoperative Pain for Laminectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~• 18 - 80 years old of either gender, scheduled for elective lumbar laminectomy~Exclusion Criteria:~* American Society of Anesthesiologists (ASA) IV and above~* Intolerance, allergy, or contraindication to use of any medications used in this study~* Significant coronary artery disease (abnormal stress test, myocardial infarction~  * within the last 3 months)~* Increased intraocular pressure (e.g., untreated glaucoma)~* Uncontrolled hypertension (BP \> 140/90)~* Sleep apnea and currently on continuous positive airway pressure (CPAP)~* Increased intracranial pressure or clinical signs thereof~* History of intracranial surgery, stroke, or brain aneurysm~* Cardiac arrhythmias particularly prolonged QT syndrome~* Drugs known to cause prolonged qT: class (IA) antiarrhythmics (quinidine, procainamide, disopyramide), class III antiarrhythmics (sotalol, dofetilide, ibutilide, amiodarone), haloperidol, thioridazine, arsenic trioxide, HIV protease inhibitors, tricyclic antidepressants~* Individuals with significant psychological disorders including: schizophrenia, mania, bipolar disorder or psychosis~* Pregnant or lactating women~* Emergent laminectomy~* Those already receiving ketamine or methadone prior to surgery~* Morbid obesity (BMI \> 40 kg/m2) AND/OR weight \> 150 kg~* Chronic renal failure ( creatinine \> 2.0 mg/dL)~* Liver failure e.g., active cirrhosis~* Alcohol or substance abuse within in the past 3 months~* Uncorrected hypokalemia, hypomagnesemia, hypocalcemia (can be due to diuretics, mineralocorticoid use, laxatives)~* Chronic obstructive pulmonary disease (COPD)/Hypercarbia~* Restrictive lung disease (pulmonary fibrosis, myasthenia gravis)~* Congestive heart failure~* Thyroid disease~* Organ transplant patients~* Drugs/substances known to inhibit methadone metabolism: macrolide antibiotics e.g., erythromycin, cimetidine, astemizole, voriconazole, grapefruit juice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: ACTIVE_COMPARATOR): A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min))
- Methadone (Type: ACTIVE_COMPARATOR): Will receive a single dose of IV methadone (0.2 mg/kg) preinduction
- Ketamine + methadone (Type: EXPERIMENTAL): Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ³ 18 years~* Low or intermediate-1 risk MDS according to IPSS, and FAB classification of RA, RARS, or RAEB with blasts £ 10%~* Predictive variables of good response (serum erythropoietin levels \< 500 IU/l and transfusion requirements \< 2 packed RBC/month over the preceding 2 months)~* Anaemia (Hb £ 10 g/dL), confirmed in the 14 days before day 1 of the study~* Life expectancy of at least 6 months~* ECOG Performance status score of 0, 1, or 2~* Subject must sign and date the Informed Consent (approved by a Clinical Research Ethics Committee - CREC), before any study-specific procedure is performed~Exclusion Criteria:~* Known history of convulsive disorders~* Poorly controlled hypertension (diastolic blood pressure \> 100 mmHg) at screening~* Inadequate liver function (total bilirubin \> two times the upper limit of the normal range (ULN), and liver enzymes (ALT, AST) \> two times ULN)~* Inadequate renal function (serum creatinine concentration \> 2 mg/dL)~* Ferritin \< 100 ng/ml or transferrin saturation index (TSI) \< 16%; Vitamin B12 deficiency (\< 200 pg/ml) or folate deficiency (\< 2 ng/ml)~* Clinically-relevant haemorrhages~* Haemolytic anaemia~* Cardiac condition: uncontrolled angina, congestive heart failure, or uncontrolled cardiac arrhythmia~* Clinically significant systemic infection or chronic inflammatory disease present at time of screening~* Any concomitant therapy used to treat MDS (including other growth factors than those described as part of this protocol, chemotherapy, antibody-based cancer treatment, hormonal therapy, interferon, and interleukins)~* Treatment with rHuEPO or darbepoetin alfa over the 4 weeks prior to Day 1 of the study~* More than 2 RBC transfusions over the 28 days prior to Day 1 of the study~* Pregnant or breast feeding women~* Subjects of childbearing-potential who do not take adequate contraceptive measures, in the opinion of the investigator~* Known hypersensitivity to any mammal-derived recombinant product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Juvista (Avotermin) in Breast Reduction Surgery Scars

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female patients between 18 and 65 years of age undergoing bilateral reduction mammaplasty with anchor shaped incisions, who have given written informed consent.~* Patients with a Body Mass Index of 15-32 kg/m2 inclusive.~* Patients of child bearing potential who are using method(s) of contraception acceptable to the Investigator and agree to do so from at least the screening visit until 1 month after administration of the trial investigational products.~* Patients with, in the opinion of the Investigator, clinically acceptable results for the laboratory tests specified in the trial protocol.~Exclusion Criteria:~* Patients with significant breast asymmetry that may result in asymmetrical operative incisions being made on the left and rights breasts.~* Patients with breast asymmetry that may result in different post-operative tensions on the wounds of the left and right breasts.~* Patients who have had surgery in the area to be incised within one year of trial surgery.~* Patients with a history of a bleeding disorder.~* Patients with a history of breast malignancy.~* Patients with a skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the wounds or involves the areas to be examined in this trial.~* Patients who on direct questioning and/or physical examination, have evidence of any past or present clinically significant medical condition that would impair wound healing.~* Patients with a history of clinically significant hypersensitivity to any of the drugs or surgical dressings to be used in this trial.~* Patients who are taking, or have taken, any investigational drugs in the 3 months prior to the screening visit.~* Patients who are taking regular, continuous, oral corticosteroid therapy.~* Patients undergoing investigations or changes in management for an existing medical condition.~* Patients who are or who become pregnant up to and including the day of surgery or who are lactating.~* Patients with diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety or efficacy of the investigational product.~* Patients who, in the opinion of the Investigator, are not likely to complete the trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Patient eligibility criteria in accordance to the summary of Product Characteristics:~* Patients with confirmed diagnosis of acute myeloid leukemia according to the World Health Organization (WHO) classification (including de novo AML, t-AML and s-AML) in first complete remission (defined as less than 5% blasts in a normocellular bone marrow assessed prior to the treatment start)~* AMLSG BiO participation incl. favourable opinion~* Presence of NPM1 mutation, CBFB-MYH11 or MLL-AF9 fusion genes as assessed in one of the central AMLSG reference laboratories.~* Measurable MRD values (non-negative values after consolidation therapy or increase in values over the threshold during follow-up in complete remission)~* The patient must be informed of the observation and written informed consent regarding data privacy obtained.~* Consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and all other treating physicians about observation participation~* No continuing systemic treatment with clonidine, steroids, and/or H2 receptor blocking agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Lung Cancer-Related Anxiety (RELAX)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Past History of any lung cancer~* For Stage I-III disease, patients should be 2-24 months post-completion of surgery, radiation therapy and/or chemotherapy with no further planned treatment during the 12-week study and no evidence of disease.~* For Stage IV disease, patients may be receiving no treatment or may be receiving maintenance treatment with a target agent, chemotherapy, or immunotherapy provided the most recent imaging does not demonstrate progressive disease.~* After completion of all three screening questionnaires, participant must score accordingly on at least one questionnaire to be eligible.~* Willing/able to attend brief introductory session and use assigned device for the assigned period of time (15 minutes once or twice per day), at least 5 days per week for 12 weeks~* Age ≥ 18 years~* Must have telephone~Exclusion Criteria:~* Patient does not understand English~* Active lung infection~* Progressive cancer (must be considered no evidence of disease or stable)~* Any change in psychotropic medications in past 30 days~* Hearing loss that would preclude participating in interventions. Adequate hearing to participate will be determined via: (1) Response of no to the question \[Do you have a hearing problem now?\] Participants with hearing aids will be allowed to enroll as long as their hearing is adequate to hear the sounds on the study devices. If necessary, potential study participants will receive a brief test trial with the RESPeRATE device. If they indicate inability to hear the guiding tones, they will not be enrolled in the study.~Cortisol Exclusion~- Participants with endocrine disorders (e.g., diabetes and thyroid disorders) or on steroid-based medications are excluded from the cortisol portion of the study (with the exception of topical hydrocortisone that is permitted).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Group A - Device Guided Breathing Low Dose
- Group B (Type: EXPERIMENTAL): Group B - Device guided breathing high dose
- Group C (Type: SHAM_COMPARATOR): Group C - Usual Breathing Control Group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed undifferentiated nasopharyngeal cancer (UNPC)~  * Locoregionally advanced disease~    * T2b, N1 (greater than 3 cm) or N2~   * T3, N1 (greater than 3 cm) or N2~   * T4, N1 (greater than 3 cm) or N2~   * Any T, N3~ * No squamous cell histology~* At least 1 unidimensionally measurable target lesion~  * At least 20 mm by conventional techniques OR~ * At least 10 mm by spiral CT scan~* No evidence of distant metastases~* No signs or symptoms of CNS metastases~PATIENT CHARACTERISTICS:~Age:~* 15 to 70~Performance status:~* WHO 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 2,000/mm\^3~* Platelet count at least 150,000/mm\^3~* Hemoglobin at least 12 g/dL~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* AST/ALT no greater than 2.5 times ULN~Renal:~* Creatinine clearance at least 70 mL/min~* Calcium normal~Cardiovascular:~* No hypotension or hypertension requiring therapy~* No prior myocardial infraction~* No pre-existing uncontrolled cardiac disease~* No signs of cardiac failure~* No rhythm disturbances requiring medication~Other:~* No sensory neuropathy grade 2 or greater unless due to cranial nerve~* No uncontrolled infections~* No sensitivity to aminothiol compounds~* No other malignancy within the past 5 years except adequately controlled carcinoma in situ of the cervix or basal cell or squamous cell skin cancer~* No psychological, familial, sociological, or geographical condition that would preclude study~* Fertile patients must use effective contraception during and for 3 months after study~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent immunotherapy~Chemotherapy:~* No prior chemotherapy for UNPC~Endocrine therapy:~* No concurrent hormonal therapy except corticosteroids for antiemetic prophylaxis~Radiotherapy:~* No prior radiotherapy for UNPC~Surgery:~* No prior surgery for UNPC except cervical lymphadenectomy~Other:~* At least 1 month since prior investigational agent~* No other concurrent anticancer drugs

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Construct Validity of a Diagnostic Hysteroscopy Training Model

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* medical Student~* no previous experience in gynecologic surgery~* no previous gynecologic surgery Training~* gynecologist with a personal history of at least 50 hysteroscopies)~Exclusion Criteria:~* language barrier~* unwillingness to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Experts (Type: ACTIVE_COMPARATOR): Surgically experienced gynecologists with a personal history of at least 50 hysteroscopy procedures will perform a hysteroscopy on a training model.
- Novices (Type: EXPERIMENTAL): Medical students will perform a hysteroscopy on a training model.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female participants of childbearing potential must have negative pregnancy test and use appropriate contraceptive methods~* Documented GHD during adulthood~* Participants naive to somavaratan must have an IGF-1 SDS value ≤ 0 at Screening~* Participants taking other hormone replacement therapy must have been on a stable course of treatment for at least 3 months~* Underlying disorders responsible for the participant's GHD must have been clinically stable for at least 6 months~* Participants receiving daily rhGH injections must washout for ≥ 14 days~* Body mass index (BMI) (kilograms \[kg\]/meter square \[m\^2\]) between 18.0 and 40.0~Exclusion Criteria:~* Untreated adrenal insufficiency~* Recently diagnosed thyroid dysfunction which is not being treated or has not been stable on therapy for at least 3 months~* Currently taking anti-inflammatory dose of glucocorticoids that could potentially compromise safety or efficacy assessments~* Currently taking a GHRH or IGF-I product~* Current significant cardiovascular disease, heart insufficiency of New York Heart Association (NYHA) class \> 2~* Current significant disease thought to increase risk of receiving growth hormone or confound assessment of study outcomes~* History of diabetes mellitus or inadequate glucose control~* Current drug or alcohol abuse~* Current human immunodeficiency virus (HIV) wasting syndrome (HIV testing not required)~* History of malignancy in adulthood (participants with a history of childhood malignancy that were subsequently treated with rhGH in childhood and remain GHD in adulthood may be enrolled)~* Women who are pregnant or breastfeeding~* Treatment with an investigational drug other than somavaratan within 30 days prior to Screening~* A significant abnormality in Screening laboratory results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Somavaratan (Type: EXPERIMENTAL): Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly in adult participants with GHD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven hepatocellular carcinoma.~2. HCC underwent curative resection within 6 weeks before registration.~3. Grossly, the resection margin should be \> 1 cm.~4. Tumors, either single, \< 5 cm in size or no more than 3 for size \< 3 cm.~5. Patients must have a performance status of ECOG score \< 2.~6. Patients must have adequate liver reservation and adequate hemogram.~   * Pugh-Child's Score \< 7.~  * The serum total bilirubin level are \< 2 mg/dl.~  * The prothrombin times are \< 3 sec above normal control.~  * The platelet are \> 7.5 x 104 / mm3.~  * The WBC are \> 3,000 / mm3.~7. Patient must have serum creatinine \< 1.5 mg/dl~8. Cardiac function with NYHA classification \< Grade II~9. HBsAg (+) .~10. Signed informed consent.~Exclusion Criteria:~1. Patients who have non-curative resection are not eligible.~2. Resected HCCs with histologically positive margins are not eligible.~3. HCCs with radiological evidence of portal vein thrombus are not eligible.~4. Patients with other systemic diseases which required concurrent usage of glucoticosteroid or immunosuppressant agent(s) are not eligible.~5. Patients with advanced second primary malignancy are not eligible.~6. Patients with pregnancy or breast-feeding are not eligible.~7. Patients with severe cardiopulmonary diseases are not eligible.~8. Patients with clinically significant psychiatric disorder are not eligible.~9. Patients who had antineoplastic chemotherapeutic or immuno-therapeutic drugs or corticosteroids within 6 weeks of commencing the protocol are not eligible.~10. Patients who had prior lamividine and/or adefovir dipivoxil therapy are not eligible.~11. Anti-HCV positive patients are not eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to provide written informed consent~2. Diagnosis of ITP in adult patients (≥ 18 years of age) with an insufficient response to steroids ± immunoglobulins and requiring a change in therapy~3. For Cohort 1, intent to initiate fostamatinib at enrollment as change in therapy~4. For Cohort 2, currently undergoing treatment with fostamatinib as second line therapy for at least 12 weeks, with the intent to continue, at the time of enrollment~Exclusion Criteria:~1. Any prior ITP therapy/treatment other than steroids ± immunoglobulins (e.g. rituximab, thrombopoietin receptor agonists (TPO), splenectomy)~2. Participation in any interventional study during the course of this study~3. Lack of historical platelet counts, at time of fostamatinib initiation for those entering Cohort 2~4. Pregnant and/or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Initiating treatment with fostamatinib as second-line therapy (Type: None): None
- Treated with fostamatinib for at least 12 weeks as second-line therapy (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues